Clinical-stage biopharmaceutical company Immunic Inc. has signed an in-license agreement with the University Medical Center Goettingen, Germany, covering the combination of DHODH inhibitors and nucleoside analogues to treat viral infections (COVID-19 and Influenza). Terms of the agreement were not disclosed.   Inhibiting SARS-CoV-2 Replication    Preclinical research recently completed by the parties and their collaborators has shown that certain DHODH inhibitors, including Immunic’s le...